Skip Navigation
Johns Hopkins Bloomberg School of Public Health
Bookmark and Share
   

IVAC Blog

 
Keyword: disease burden

By Dr. Kate O’Brien, Executive Director, International Vaccine Access Center (IVAC)

Everyone may get 15 minutes of fame, however, for common illnesses such as pneumonia headlines are scarce. While Secretary Clinton’s pneumonia diagnosis is viewed by most through a political lens, the candidate’s announcement has also sparked a curiosity about an illness contracted by millions every year.

Pneumonia, an infection of the lungs, is exceedingly common around the world with an estimated 450 million cases annually. In the US, about a million people seek hospital care for pneumonia with a cost to the health system of more than $10 billion each year according to the American Thoracic Society.

While the cost of pneumonia in the US is staggering, in too many countries the price is even higher. In the US, we have ready access to trained physicians with the know-how and equipment to make a diagnosis and when necessary, antibiotics and oxygen to treat illness. While some may balk at the cost, these interventions have been proven effective, and the vast majority of people who contract pneumonia make a full recovery. Sadly, this is not true everywhere.

In parts of Africa and Asia resources are scarce, and HIV infections, crowding, and indoor air pollution are prevalent and put people at risk. Also, the prevention and treatment measures we take for granted, such as vaccines and hand washing, are too often not available. The price of pneumonia in these countries is higher infection rates, more illness and, sadly, more deaths, especially in children younger than five years of age.

For most of my career I have been engaged in the fight against pneumonia. I have worked with nonprofits, governments and businesses to help families everywhere have access to the tools they need to fight this illness. We have made considerable progress. Vaccines to prevent the most deadly causes of pneumonia are rapidly being deployed in countries in most need—thanks to Gavi, the Vaccine Alliance, and country governments. As more children have access to vaccines and medicine to prevent and treat pneumonia, we see less disease and fewer lives lost. Yet, much work remains. More than 900,000 young children still lose their lives to pneumonia each year, these children need access to the same tools as our children, to prevent, diagnose and treat this common illness.

There is also a need to invest in innovations that will help those who contract pneumonia in the US and around the world. For example, pneumonia can have bacterial, viral, or occasionally fungal causes. Currently, there is no reliable test that will identify the cause of the infection in every case. The conventional method involves imaging, bloodwork, or cultures that are inconclusive in more cases than not. Physicians typically treat with antibiotics in case the infection is bacterial, but often the pathogen remains unknown. A test to identify the pathogen would help health workers everywhere to treat pneumonia appropriately and reduce unwarranted antibiotic use, this will help to address issues of antimicrobial resistance which threaten to undermine our ability to treat infections.

More than anything else, there is a need to put pneumonia on our collective radar as a public health problem that requires attention. Last year, pneumonia took more young lives than Zika, Ebola, malaria, tuberculosis, and HIV combined. Globally pneumonia is the leading cause of death for children under five years of age. Yet, pneumonia flies under the radar; it is so common that it is nearly invisible.

Can this change? Absolutely. This week, pneumonia is in the headlines and people are talking about their experience (or their parent’s or their child’s) with the illness. While pneumonia’s 15 minutes of fame may be about to run out, the chance to make a difference remains.

Kate O’Brien, MD, MPH is the Executive Director of the International Vaccine Access Center and Professor at the Johns Hopkins Bloomberg School of Public Health. She is a pediatric infectious disease physician, epidemiologist and vaccinologist. 

By Jillian Murray

 “Influenza… what about HIV? That’s what people are dying from here.”

These are the words I heard in countless conversations while working on an influenza research project in South Africa last summer. Nearly every time I mentioned I was working on a public health research project I was met with a chorus of “ohhh HIV.” After explaining that I was, in fact, researching influenza, the conversation usually shifted to wondering why I would focus on something other than HIV.

I remember leaving some people unconvinced of the importance of studying respiratory diseases. Many had an emotional connection to HIV and recounted stories of people they knew dying of AIDS, but were unable to recall someone who died of influenza. In some populations, this acute awareness of the devastation of the HIV/AIDS epidemic has led to an ideology where an HIV diagnosis is mutually exclusive of other diseases.

Jillian Murray and a colleague.

Jillian Murray and a colleague in the Soweto township in Johannesburg during interviews for a health survey.

I found it interesting to witness the distinct hierarchy in the perceived importance of certain diseases. Influenza causes annual worldwide epidemics and can be a life-threatening complication of many other diseases, but because many people rank it’s severity slightly above the common cold, it is often assumed to be rather harmless. This is not only true in settings where there are other high priority communicable diseases, but is a common perception in North America as well.

The true burden of influenza is not well described in many developing countries. However, the burden is expected to be higher in developing compared to developed countries because of underlying factors that contribute to greater severity of disease – factors like crowding, low birth-weight, malnutrition and HIV, among others. In contrast to developed countries where the burden is primarily in the elderly population, these socio-economic factors play a role in broadening the demographic that is most at-risk for severe influenza in South Africa.

A better understanding of the burden of influenza is important for pandemic planning and more effective distribution of vaccine supply. While in South Africa, I worked under the supervision of Daniel Feikin, IVAC’s Director of Epidemiology. With the help of researchers at the National Institute of Communicable Diseases, we used a statistical model that adjusted for influenza risk factors between different provinces to estimate the burden of severe influenza at the provincial and national levels.

As it turned out, my work was very much related to HIV, which severely compromises the immune systems of those affected. There is evidence that HIV-positive individuals suffer a much greater mortality rate from influenza than HIV-negative individuals and that the risk for acquiring influenza in HIV-positive individuals is much greater than in HIV-negative individuals. A high prevalence of HIV, such as exists in South Africa, can cause the burden of influenza to be much greater than you would expect in a population with low HIV prevalence. For these reasons, HIV became one of the most influential risk factors for which we controlled in our study.

An important aim of the burden study in South Africa was to guide public health authorities in the country on how their policies regarding influenza vaccination can better meet the needs of their population. The HIV prevalence in South Africa, while varied between provinces, averages 17% in the 15-49 age group. It is crucial for public health officials to understand the disproportionate risk people in this age cohort have of developing severe influenza infections, and to develop policies and programs accordingly.  

My conversations about why I was researching influenza were both valuable learning and teaching opportunities for me. The devastating HIV epidemic in South Africa is inextricably linked to increased susceptibility of its population to concomitant infections, such as severe cases of influenza. Therefore, it is important that discussions of HIV and influenza overlap in order to reinforce in the public’s mind the relationship these diseases have with each another. I hope I was able to play a role – however small – in increasing this understanding.

 

Jillian Murray is a second year Master of Science in Public Health (MSPH) student in the Global Disease Epidemiology and Control program at Johns Hopkins Bloomberg School of Public Health.

Calendar
Sep 2016  
 123
45678910
11121314151617
18192021222324
252627282930